> Detailanzeige

Cavalieri, Stefano; Colombo, Elena; Bottiglieri, Achille; Massa, Giacomo; Platini, Francesca; Ottini, Arianna; Filippini, Daria Maria; Zattarin, Emma; Bergamini, Cristiana; Resteghini, Carlo; Alfieri, Salvatore; Di Martino, Vito; Tiraferri, Valentina; Locati, Laura Deborah; Licitra, Lisa

Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic
  • Beteiligte: Cavalieri, Stefano; Colombo, Elena; Bottiglieri, Achille; Massa, Giacomo; Platini, Francesca; Ottini, Arianna; Filippini, Daria Maria; Zattarin, Emma; Bergamini, Cristiana; Resteghini, Carlo; Alfieri, Salvatore; Di Martino, Vito; Tiraferri, Valentina; Locati, Laura Deborah; Licitra, Lisa
  • Erschienen: SAGE Publications, 2022
  • Erschienen in: Tumori Journal
  • Sprache: Englisch
  • DOI: 10.1177/03008916211007940
  • ISSN: 0300-8916; 2038-2529
  • Schlagwörter: Cancer Research ; Oncology ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Objective:</jats:title><jats:p> To capture and monitor flu-like symptoms in relation to the clinical characteristics and the oncologic treatment of a large head and neck cancer (HNC) patient cohort during the Coronavirus disease 2019 (COVID-19) pandemic. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Patients were monitored through by 2 rounds of interviews. Clinical characteristics of patients with no symptoms (group 0) and of those reporting ⩾1 (group A), ⩾3 (group B), or ⩾5 symptoms (group C) were analyzed. Patients with ⩾1 symptom at both interviews were defined as group A2. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Five hundred patients with HNC were analyzed. A higher frequency of patients with the following characteristics was observed in group A vs group 0: active treatment (40% vs 24%, p = 0.0002), gastrostomy (6% vs 2%, p = 0.027), recent active treatment (48% vs 29%, p &lt; 0.0001), and higher number of concomitant medications ( p = 0.01). A lower median age was observed in group B vs group no-B (patients with fewer than three symptoms) (59 vs 63.55 years, p = 0.016) and in group A2 vs group no-A2 (patients without at least one symptom at both interviews) (56 vs 63 years, p = 0.021); patients in group B received more recent active treatment than those in group no-B and in group A2 vs those in group no-A2 ( p = 0.024 and 0.043, respectively); patients in group B had a lower body mass index than those in group no-B (22.4 vs 23.93 kg/m<jats:sup>2</jats:sup>, p = 0.0066). </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> This work is based on patient-reported symptoms and signs independently of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. In the future, these results might serve as a a benchmark for clinicians triaging and managing patients with HNC during infectious outbreaks involving flu-like symptoms. </jats:p></jats:sec>